entertainment -WSS

entertainment

author：hotspot 2025-10-02 01:08:01 - browse：385

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

hotspot

WSS

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

FDA's Pazdur wants cancer trials to range beyond China alone

BMI, flaws aside, is found to be useful estimate of body fat in youth

Readout LOUD podcast: A CRISPR milestone, biotech mixology

U.K. considers world's first use of meningitis vaccine to address gonorrhea

The Pandemic Treaty must support building strong health systems

explore

entertainment

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Activists slam private health insurers over coverage restrictions

FDA's Woodcock to retire early next year

Virginia high school admissions case could be legal follow

ASCO: Palliative care found as helpful given virtually as in person

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to increase colonoscopy rates? Looks like an AI can help

hotspot

Ultragenyx gene therapy for rare liver ailment succeeds in late

BMI, flaws aside, is found to be useful estimate of body fat in youth

Anthos stroke drug appears safer than common blood thinner

Morphosys mixed study results for blood cancer drug

Let's speed up science by embracing open access publishing

Ionis drug prevents swelling attacks due to hereditary angioedema

knowledge

hotspot

hotspot

entertainment